Voyager Therapeutics Inc is a pioneering company dedicated to developing transformative gene therapies for severe neurological diseases. With a strong commitment to patients, Voyager Therapeutics strives to deliver innovative treatments that can significantly improve their quality of life. The company's corporate philosophy is centered around integrity, innovation, and collaboration. By combining cutting-edge science, advanced technologies, and a multidisciplinary approach, Voyager Therapeutics aims to unlock the potential of gene therapy and create new opportunities for patients suffering from neurological disorders. Through their unwavering dedication and expertise, Voyager Therapeutics is poised to revolutionize the field of gene therapy and address unmet medical needs.

Voyager Therapeutics Inc is primarily present in the United States.

Voyager Therapeutics Inc has achieved significant milestones in the field of gene therapy. The company has successfully developed and advanced several programs aimed at treating severe neurological diseases. One notable accomplishment includes the initiation of a phase 2 clinical trial for VY-AADC, a potential treatment for Parkinson's disease. Voyager also entered into a collaboration with AbbVie to develop gene therapies for Alzheimer's disease, tauopathies, and severe neurological diseases. Additionally, Voyager has forged partnerships with leading academic institutions and organizations, further solidifying its position as a prominent player in the field of gene therapy.

Voyager Therapeutics Inc is a biopharmaceutical company focused on developing gene therapies for severe neurological diseases. Founded in 2013, the company aims to address the significant unmet need in the field of neurodegenerative disorders. Voyager Therapeutics leverages its expertise in gene therapy to deliver transformative treatments for diseases such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The company collaborates with renowned institutions and has a robust pipeline of potential therapies. With a commitment to improving patients' lives, Voyager Therapeutics continues to make advancements in the field of gene therapy and neurology.

The main competitors of Voyager Therapeutics Inc in the market include companies such as Axovant Gene Therapies Ltd, uniQure N.V., and Solid Biosciences Inc.

Voyager Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Voyager Therapeutics Inc. focuses on developing gene therapies for severe neurological diseases. By harnessing the power of the central nervous system's ability to produce proteins, Voyager aims to address genetic deficiencies that cause these diseases. The company utilizes viral vectors to deliver therapeutic genes to the targeted areas of the brain, aiming to provide long-term benefits to patients. Voyager's expertise lies in the development of innovative treatments for Parkinson's disease, Huntington's disease, and other genetic disorders. Through its gene therapy platform, Voyager Therapeutics Inc. strives to improve the lives of individuals living with these debilitating conditions.

P/E odnos Voyager Therapeutics iznosi -4,68.

KUV kompanije Voyager Therapeutics iznosi 7,90.

AlleAktien kvalitativni skor za Voyager Therapeutics je 5/10.

očekivana Voyager Therapeutics promet je 49,48 mil. USD.

Dobit očekivana Voyager Therapeutics je -83,51 mil. USD.

Voyager Therapeutics Inc. is a gene therapy company focused on developing therapies for genetic diseases. The company's business model is based on the development and commercialization of gene therapies for severe and rare diseases. By focusing on gene therapy, the company is aligned with developing effective treatments and enjoys a competitive advantage as the gene therapy market is still relatively new. Voyager Therapeutics has three types of gene therapies in its pipeline, including adeno-associated virus (AAV) gene therapies, ex-vivo gene therapies, and therapies for neurodegenerative diseases. In addition to developing therapies, the company also offers services such as clinical trials and gene therapy production. Voyager Therapeutics aims to make gene therapy the standard for treating severe diseases and plans to expand into other industries through licensing its technology and collaborating with other companies. The company has partnerships with major biotech and pharmaceutical companies to access resources and improve its scientific and technical capabilities. Overall, Voyager Therapeutics' business model aims to develop and market gene therapies to address unmet medical needs in rare and severe diseases, while also expanding its presence in other industries.

Voyager Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Voyager Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Voyager Therapeutics je US92915B1061.

WKN od Voyager Therapeutics je A143XJ.

Oznaka za praćenje akcija kompanije Voyager Therapeutics je VYGR.

U poslednjih 12 meseci, Voyager Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Voyager Therapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Voyager Therapeutics trenutno iznosi .

Voyager Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Voyager Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Voyager Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Voyager Therapeutics od 13. 7. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 13. 7. 2024..

Isplata poslednje dividende izvršena je 13. 7. 2024..

U godini 2023 kompanija Voyager Therapeutics je isplatila 0 USD kao dividende.

Dividende od Voyager Therapeutics se isplaćuju u USD.